Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NUDT19 divergent transcript (NUDT19-DT) refers to a non-coding RNA gene, annotated as an RNA gene associated with the NUDT19 locus. Unlike NUDT19 (Nudix hydrolase 19), which is a protein-coding gene and a known metabolic enzyme, NUDT19-DT is not characterized as an enzyme, receptor, transporter, or otherwise typical therapeutic target. Evidence does not support a functional protein product or therapeutic relevance for NUDT19-DT; it may function in gene regulation or simply represent transcriptional noise. No known drugs, molecular mechanisms, disease associations, or biomarker uses have been described for NUDT19-DT in the scientific literature or major biomedical databases. NUDT19-DT is not recognized as a druggable target, nor as a receptor, enzyme, transporter, or similar molecular entity relevant to drug development and pharmacology. All known biomedical relevance and druggability pertains to NUDT19, not its divergent transcript.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NUDT19 divergent transcript (NUDT19-DT).